What to expect after natalizumab cessation in a real-life setting. - Wikidata - awgldk - TriplyDB

What to expect after natalizumab cessation in a real-life setting.

What to expect after natalizumab cessation in a real-life setting.

http://www.wikidata.org/entity/Q44012129

about

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.Disease activity return after natalizumab cessation in multiple sclerosis.Efficiency of antibody therapy in demyelinating diseases.Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.Real-life clinical use of natalizumab and fingolimod in Austria.Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report

P2860

Q26781389-F0690B35-BED9-4B5F-B831-B69FBC1DC744 Q33562198-894BD1CD-F3BD-4443-8564-C168F8B4E1B2 Q37045253-90612BBA-7413-4089-B27C-1E6945BC2E5B Q38268313-348CD7EB-91A5-41DC-8972-0CB09A135F54 Q38779091-44189B22-879F-465E-9AD4-55F4450DB7EB Q40045794-66F380C5-EC9D-4E73-96E8-0C651BD3AF13 Q40747927-D47D37D8-5AAD-4F49-9C71-4962FE6CCB6E Q41386664-D3DD5745-D500-4634-8495-8F983E060526 Q47437600-8E1BD12F-3D37-40EF-BD18-79EB585BEE17 Q57913814-5805DEA6-D9D3-4017-8B4F-1E9FAB6CE0DF

P2860

What to expect after natalizumab cessation in a real-life setting.

http://www.wikidata.org/entity/Q44012129

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

What to expect after natalizumab cessation in a real-life setting.

@en

What to expect after natalizumab cessation in a real-life setting.

@nl

type

label

What to expect after natalizumab cessation in a real-life setting.

@en

What to expect after natalizumab cessation in a real-life setting.

@nl

prefLabel

What to expect after natalizumab cessation in a real-life setting.

@en

What to expect after natalizumab cessation in a real-life setting.

@nl

P1433

Q44012129-E125334A-8003-47BD-AB5D-0575A79C0EF0

P1476

Q44012129-1A161264-24BB-44E1-BFCF-ABEDC35879FB

P2093

Q44012129-13390F77-ED32-4E26-ADFD-2B500E5E0A2B

Q44012129-135550AF-0C81-4983-AE25-574162E3D363

Q44012129-2EBC4C99-1F89-4D52-8264-E2D28DD56438

Q44012129-93826774-D979-4FDE-92F1-24BA9F780A06

Q44012129-A792F7F8-830E-4065-A278-B11844C1B0A9

Q44012129-CA1E7864-DB34-49E5-BBD1-4F4CEBFD1BC0

P2860

Q44012129-15D98647-60AD-4AB5-BDED-F411A1940B70

Q44012129-18D33584-3EE5-42E7-A08A-201189782ED5

Q44012129-2B9E3473-7674-4D2E-9FBC-19C24294CF67

Q44012129-3FD82C6E-8B67-47E7-9612-2CA0109079B3

Q44012129-853B15F7-83BB-4058-AA83-D1C9CAADBB80

Q44012129-9FD4358D-DF58-4DF2-9277-1B25898C2B25

Q44012129-A3797CF6-AE6D-4340-A43B-D6A410EDE062

Q44012129-AB2EB6AF-B6BC-4CAD-BCF8-5A25E249547D

Q44012129-B1C78BA3-EB52-4D9A-9620-9229D1C77FC7

Q44012129-BAB4BDCB-62E6-4352-BAC0-88E5DEFB8940

P304

Q44012129-05138B2F-919F-4010-A904-F71262C11ED7

P31

Q44012129-8E31E98F-95DD-49EE-8CB9-798566251852

P356

Q44012129-7077A9AC-374D-4602-B1B4-4895998CE8B3

P407

Q44012129-404F9F72-762A-4647-8B79-8882AE6D8FAE

P433

Q44012129-44D11635-9068-41AE-A396-01262891FAB8

P478

Q44012129-7D1EFEF7-6420-4F9D-B3F3-AFBB827CCD2A

P577

Q44012129-5F20791E-E04B-4E26-99F0-C76BC85D428A

P698

Q44012129-B4E93E3B-3F96-4339-8C9C-4B6D804546B1

P356

P1433

Acta Neurologica Scandinavica

P1476

What to expect after natalizumab cessation in a real-life setting.

@en

P2093

A Baumgartner

http://www.w3.org/2001/XMLSchema#string

E Maida

http://www.w3.org/2001/XMLSchema#string

F Leutmezer

http://www.w3.org/2001/XMLSchema#string

J Kraus

http://www.w3.org/2001/XMLSchema#string

M Schmied

http://www.w3.org/2001/XMLSchema#string

S Salhofer-Polanyi

http://www.w3.org/2001/XMLSchema#string

P2860

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab.

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.

Immune cells after prolonged Natalizumab therapy: implications for effectiveness and safety.

Natalizumab drug holiday in multiple sclerosis: poorly tolerated.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

P304

97-102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ANE.12250

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24720783

http://www.w3.org/2001/XMLSchema#string